Jagsonpal Pharma

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE048B01035
  • NSEID: JAGSNPHARM
  • BSEID: 507789
INR
179.50
10.5 (6.21%)
BSENSE

Feb 03

BSE+NSE Vol: 99.31 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy
Comparison
Company
Score
Quality
Valuation
Financial
Technical
Kwality Pharma
Venus Remedies
NGL Fine Chem
Fermenta Biotec.
Shukra Pharma.
Amrutanjan Healt
Syncom Formul.
Hester Bios
Jagsonpal Pharma
Bajaj Healthcare
Beta Drugs Ltd
Why is Jagsonpal Pharmaceuticals Ltd ?
1
With ROE of 17, it has a Very Expensive valuation with a 5.7 Price to Book Value
  • The stock is trading at a discount compared to its peers' average historical valuations
  • Over the past year, while the stock has generated a return of -23.17%, its profits have risen by 60.3% ; the PEG ratio of the company is 0.6
2
Despite the size of the company, domestic mutual funds hold only 0% of the company
  • Domestic mutual funds have capability to do in-depth on-the-ground research on companies- their small stake may signify either they are not comfortable at the price or the business
3
Underperformed the market in the last 1 year
  • Even though the market (BSE500) has generated returns of 2.35% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -23.17% returns
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Jagsonpal Pharma for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Jagsonpal Pharma
-30.16%
-0.42
54.85%
Sensex
8.49%
0.44
11.83%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
10.03%
EBIT Growth (5y)
26.90%
EBIT to Interest (avg)
32.56
Debt to EBITDA (avg)
0.30
Net Debt to Equity (avg)
-0.59
Sales to Capital Employed (avg)
1.31
Tax Ratio
24.93%
Dividend Payout Ratio
58.85%
Pledged Shares
0
Institutional Holding
2.27%
ROCE (avg)
36.15%
ROE (avg)
16.16%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
28
Industry P/E
32
Price to Book Value
4.75
EV to EBIT
22.73
EV to EBITDA
18.87
EV to Capital Employed
10.25
EV to Sales
3.73
PEG Ratio
1.50
Dividend Yield
1.39%
ROCE (Latest)
44.66%
ROE (Latest)
16.86%
Loading Valuation Snapshot...
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

4What is working for the Company
ROCE(HY)

Highest at 21.66%

CASH AND CASH EQUIVALENTS(HY)

Highest at Rs 159.24 cr

0What is not working for the Company
Icon
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...
Here's what is working for Jagsonpal Pharma
Cash and Cash Equivalents - Half Yearly
Highest at Rs 159.24 cr
in the last six half yearly periods
MOJO Watch
Short Term liquidity is improving

Cash and Cash Equivalents